Targeted Immuno Cancer Drug Cost Calculator

Targeted Immuno Cancer Drug Cost Calculator helps estimate Korea-related cancer surgery, cancer drug, reimbursement, and treatment reserve scenarios in English.

Targeted and immunotherapy cancer drug cost calculator

Uses the Korean targeted and immunotherapy drug model for drug preset, monthly price, cycle, covered, selective-benefit or non-covered status, cancer special-case 5 percent copay, copay ceiling, cancer rider, private indemnity, and tax credit.

Korean source inputs

Final after insurance and tax

₩346,000

Final targeted or immunotherapy treatment-window estimate

Patient payment before offsets

N/A

NHI copay, non-covered items, room, and selected add-ons before private reimbursement and tax credit.

Estimated private reimbursement

₩1,384,000

Uses the Korean source generation rules.

Estimated tax credit

₩0

Medical expense credit follows the Korean 3 percent salary threshold and 15 percent credit model.

Cost range

₩311,400 - ₩397,900

Low and high estimate from the source model.

Applied NHI copay

5.0%

Before private indemnity reimbursement.

Non-covered total

N/A

Self-pay items outside ordinary covered medical benefit.

Monthly drug price

₩7,000,000

타그리소 (오시머티닙)

Ceiling refund

₩2,470,000

Korean annual copay ceiling applied to covered self-pay.

Covered vs non-covered gap

₩82,270,000

Annual difference in the source comparison.

The English calculator calls the same Korean pure function as the Korean page; labels are translated, not re-modeled.

Related calculators

Targeted and immunotherapy cancer drug cost calculator

This page translates the Korean targeted and immunotherapy cancer drug guide for monthly drug price, cycle, covered, selective-benefit, and non-covered status, cancer special-case registration, copay ceiling, rider reimbursement, indemnity, and tax credit.

Drug presets

The Korean source models Tagrisso at KRW 7,000,000 per month, Leclaza at KRW 6,000,000, Gleevec at KRW 2,000,000, Herceptin at KRW 2,200,000, Ibrance at KRW 5,000,000, Lynparza at KRW 6,000,000, Keytruda at KRW 6,500,000, Opdivo at KRW 6,000,000, Tecentriq at KRW 6,000,000, Imfinzi at KRW 7,000,000, and Yervoy at KRW 9,000,000.

Coverage can be covered, selective benefit, or non-covered. Selective benefit uses a user-selected 30 percent, 50 percent, or 80 percent copay. Non-covered drug cost is modeled as 100 percent self-pay before private insurance and rider assumptions.

Cancer special-case and reimbursement

Cancer special-case registration uses a 5 percent copay for covered drug therapy. The model also applies income-decile copay ceiling logic and a KRW 50,000,000 annual private indemnity limit assumption.

Cancer rider reimbursement is modeled separately from indemnity reimbursement. This is important for non-covered immunotherapy because a policy may reimburse the rider portion while indemnity still applies generation-specific covered and non-covered copays.

Planning limits

Drug indication, genetic mutation, line of therapy, dose, hospital setting, cycle, reimbursement criteria, and insurer review can change the result. The calculator keeps those cost levers explicit rather than reducing the page to one percentage of drug price.